About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 564645, 12 pages
http://dx.doi.org/10.1155/2013/564645
Review Article

Metabolic Factors and Chronic Hepatitis C: A Complex Interplay

Section of Gastroenterology, DiBiMIS, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy

Received 29 April 2013; Accepted 29 June 2013

Academic Editor: Haruki Komatsu

Copyright © 2013 Fabio Salvatore Macaluso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “The global burden of hepatitis C,” Liver International, vol. 29, no. 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Petta, “Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors?” Digestive and Liver Disease, vol. 44, no. 5, pp. 359–360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Bugianesi, F. Salamone, and F. Negro, “The interaction of metabolic factors with HCV infection: does it matter?” Journal of Hepatology, vol. 56, supplement 1, pp. S56–S65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Bugianesi, A. J. McCullough, and G. Marchesini, “Insulin resistance: a metabolic pathway to chronic liver disease,” Hepatology, vol. 42, no. 5, pp. 987–1000, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Zimmet and K. G. M. M. Alberti, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Petta, C. Cammà, V. D. Marco et al., “Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection,” American Journal of Gastroenterology, vol. 103, no. 5, pp. 1136–1144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Shintani, H. Fujie, H. Miyoshi et al., “Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance,” Gastroenterology, vol. 126, no. 3, pp. 840–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Moucari, T. Asselah, D. Cazals-Hatem et al., “Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis,” Gastroenterology, vol. 134, no. 2, pp. 416–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Negro, “Abnormalities of lipid metabolism in hepatitis C virus infection,” Gut, vol. 59, no. 9, pp. 1279–1287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Hui, A. Sud, G. C. Farrell et al., “Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression,” Gastroenterology, vol. 125, no. 6, pp. 1695–1704, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Arase, F. Suzuki, Y. Suzuki et al., “Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C,” Hepatology, vol. 49, no. 3, pp. 739–744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Vanni, M. L. Abate, E. Gentilcore et al., “Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C,” Hepatology, vol. 50, no. 3, pp. 697–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Parvaiz, S. Manzoor, H. Tariq, F. Javed, K. Fatima, and I. Qadri, “Hepatitis C virus infection: molecular pathways to insulin resistance,” Virology Journal, vol. 8, article 474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Y. Sheikh, J. Choi, I. Qadri, J. E. Friedman, and A. J. Sanyal, “Hepatitis C virus infection: molecular pathways to metabolic syndrome,” Hepatology, vol. 47, no. 6, pp. 2127–2133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Stepanova, N. Rafiq, and Z. M. Younossi, “Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study,” Gut, vol. 59, no. 10, pp. 1410–1415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. I. H. Y. Cua, J. M. Hui, J. G. Kench, and J. George, “Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C,” Hepatology, vol. 48, no. 3, pp. 723–731, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Cammà, S. Bruno, V. Di Marco et al., “Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C,” Hepatology, vol. 43, no. 1, pp. 64–71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Svegliati-Baroni, F. Ridolfi, A. Di Sario et al., “Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways,” Hepatology, vol. 29, no. 6, pp. 1743–1751, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Giordanino, S. Ceretto, S. Bo et al., “Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study,” Digestive and Liver Disease, vol. 44, no. 5, pp. 406–412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Cammà, S. Petta, V. Di Marco et al., “Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis,” Hepatology, vol. 49, no. 1, pp. 195–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Vincent, M. Montagnani, and M. J. Quon, “Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium,” Current Diabetes Reports, vol. 3, no. 4, pp. 279–288, 2003. View at Scopus
  23. Y. Iwakiri and R. J. Groszmann, “Vascular endothelial dysfunction in cirrhosis,” Journal of Hepatology, vol. 46, no. 5, pp. 927–934, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C.-L. Chen, H.-I. Yang, W.-S. Yang et al., “Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan,” Gastroenterology, vol. 135, no. 1, pp. 111–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Nkontchou, J.-P. Bastard, M. Ziol et al., “Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis,” Journal of Hepatology, vol. 53, no. 5, pp. 827–833, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Petta and A. Craxì, “Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association,” Current Pharmaceutical Design, vol. 16, no. 6, pp. 741–752, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Romero-Gómez, M. Del Mar Viloria, R. J. Andrade, et al., “Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients,” Gastroenterology, vol. 128, pp. 636–641, 2005.
  28. H. S. Conjeevaram, D. E. Kleiner, J. E. Everhart et al., “Race, insulin resistance and hepatic steatosis in chronic hepatitis C,” Hepatology, vol. 45, no. 1, pp. 80–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Poustchi, F. Negro, J. Hui et al., “Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3,” Journal of Hepatology, vol. 48, no. 1, pp. 28–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. De Nicola, A. Aghemo, M. Grazia Rumi et al., “Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4,” Hepatology, vol. 55, no. 2, pp. 336–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Deltenre, A. Louvet, M. Lemoine et al., “Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis,” Journal of Hepatology, vol. 55, no. 6, pp. 1187–1194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Grasso, F. Malfatti, P. D. Leo et al., “Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin,” Journal of Hepatology, vol. 51, no. 6, pp. 984–990, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Franceschini, S. Realdon, M. Marcolongo, S. Mirandola, G. Bortoletto, and A. Alberti, “Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?” Hepatology, vol. 54, no. 2, pp. 484–494, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Fattovich, G. Svegliati Baroni, M. Pasino et al., “Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome,” Digestive and Liver Disease, vol. 44, no. 5, pp. 419–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Petta, M. Amato, D. Cabibi et al., “Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1,” Hepatology, vol. 52, no. 5, pp. 1543–1552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Poynard, V. Ratziu, J. McHutchison et al., “Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C,” Hepatology, vol. 38, no. 1, pp. 75–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Petta, C. Rosso, R. Leung, et al., “Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C,” Clinical Gastroenterology and Hepatology, vol. 11, pp. 311–317, 2013.
  38. L. Serfaty, X. Forns, T. Goeser, et al., “Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1,” Gut, vol. 61, pp. 1473–1480, 2012. View at Publisher · View at Google Scholar
  39. Z. Younossi, F. Negro, L. Serfaty, et al., “The homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial,” Hepatology, 2013. View at Publisher · View at Google Scholar
  40. L. E. Adinolfi, M. Gambardella, A. Andreana, M.-F. Tripodi, R. Utili, and G. Ruggiero, “Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity,” Hepatology, vol. 33, no. 6, pp. 1358–1364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. K. C. Thomopoulos, V. Arvaniti, A. C. Tsamantas et al., “Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis,” European Journal of Gastroenterology and Hepatology, vol. 18, no. 3, pp. 233–237, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Lonardo, L. E. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, and C. P. Day, “Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extraepatic disease,” Gastroenterology, vol. 126, no. 2, pp. 586–597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Mihm, A. Fayyazi, H. Hartmann, and G. Ramadori, “Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype,” Hepatology, vol. 25, no. 3, pp. 735–739, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Abid, V. Pazienza, A. De Gottardi et al., “An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation,” Journal of Hepatology, vol. 42, no. 5, pp. 744–751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Piodi, P. Chouteau, H. Lerat, C. Hézode, and J.-M. Pawlotsky, “Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis,” Hepatology, vol. 48, no. 1, pp. 16–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Negro, “Mechanisms and significance of liver steatosis in hepatitis C virus infection,” World Journal of Gastroenterology, vol. 12, no. 42, pp. 6756–6765, 2006. View at Scopus
  47. C. Z. Larter and G. C. Farrell, “Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?” Journal of Hepatology, vol. 44, no. 2, pp. 253–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Petta, C. Cammà, V. Di Marco et al., “Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1,” Hepatology, vol. 48, no. 1, pp. 28–37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Petta, C. Tripodo, S. Grimaudo et al., “High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis,” Digestive and Liver Disease, vol. 43, no. 5, pp. 404–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Mihm, “Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes,” Digestive Diseases, vol. 28, no. 1, pp. 280–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. H. M. Patton, K. Patel, C. Behling et al., “The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients,” Journal of Hepatology, vol. 40, no. 3, pp. 484–490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Leandro, A. Mangia, J. Hui et al., “Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data,” Gastroenterology, vol. 130, no. 6, pp. 1636–1642, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Fartoux, O. Chazouillères, D. Wendum, R. Poupon, and L. Serfaty, “Impact of steatosis on progression of fibrosis in patients with mild hepatitis C,” Hepatology, vol. 41, no. 1, pp. 82–87, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Castéra, C. Hézode, F. Roudot-Thoraval et al., “Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies,” Gut, vol. 52, no. 2, pp. 288–292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Okuda, K. Li, M. R. Beard et al., “Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein,” Gastroenterology, vol. 122, no. 2, pp. 366–375, 2002. View at Scopus
  56. H. Lerat, M. Honda, M. R. Beard et al., “Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus,” Gastroenterology, vol. 122, no. 2, pp. 352–365, 2002. View at Scopus
  57. A. Kitase, K. Hino, T. Furutani et al., “In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis,” Journal of Gastroenterology, vol. 40, no. 6, pp. 617–624, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. P. A. Gochee, J. R. Jonsson, A. D. Clouston, N. Pandeya, D. M. Purdie, and E. E. Powell, “Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-α and cytochrome P450 2E1,” Journal of Gastroenterology and Hepatology, vol. 18, no. 4, pp. 386–392, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Hora, F. Negro, G. Leandro, et al., “Is connective tissue growth factor (CTGF) the missing link between steatosis, insulin resistance and fibrosis in patients with chronic hepatitis C?” Journal of Hepatology, vol. 44, supplement 2, p. S199, 2006.
  60. S. Aleffi, I. Petrai, C. Bertolani et al., “Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells,” Hepatology, vol. 42, no. 6, pp. 1339–1348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. J. Walsh, D. M. Vanags, A. D. Clouston et al., “Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury,” Hepatology, vol. 39, no. 5, pp. 1230–1238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Seidel, X. Volkmann, F. Länger et al., “The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum,” Hepatology, vol. 42, no. 1, pp. 113–120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. J. R. Pekow, A. K. Bhan, H. Zheng, and R. T. Chung, “Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis,” Cancer, vol. 109, no. 12, pp. 2490–2496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Moriya, H. Yotsuyanagi, Y. Shintani et al., “Hepatitis C virus core protein induces hepatic steatosis in transgenic mice,” Journal of General Virology, vol. 78, no. 7, pp. 1527–1531, 1997. View at Scopus
  65. D. Moradpour, C. Englert, T. Wakita, and J. R. Wands, “Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein,” Virology, vol. 222, no. 1, pp. 51–63, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Tanaka, K. Moriya, K. Kiyosawa, K. Koike, F. J. Gonzalez, and T. Aoyama, “PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 683–694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. W. S. Lim, D. L. Ng, S. B. Kor, et al., “Tumour necrosis factor alpha down-regulates the expression of PPARalpha in human hepatocarcinoma HepG2 cells by activation of NF-kB pathway,” Cytokine, vol. 61, pp. 266–274, 2013. View at Publisher · View at Google Scholar
  68. M. J. Walsh, J. R. Jonsson, M. M. Richardson et al., “Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1,” Gut, vol. 55, no. 4, pp. 529–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Kotronen, M. Peltonen, A. Hakkarainen et al., “Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors,” Gastroenterology, vol. 137, no. 3, pp. 865–872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Valenti, A. Al-Serri, A. K. Daly et al., “Homozygosity for the patatin-like phospholipase-3/adiponutrin i148 m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 4, pp. 1209–1217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Valenti, M. Rumi, E. Galmozzi et al., “Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C,” Hepatology, vol. 53, no. 3, pp. 791–799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. E. Shoelson, L. Herrero, and A. Naaz, “Obesity, inflammation, and insulin resistance,” Gastroenterology, vol. 132, no. 6, pp. 2169–2180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. J.-P. Després and I. Lemieux, “Abdominal obesity and metabolic syndrome,” Nature, vol. 444, no. 7121, pp. 881–887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. D. C. Chan, G. F. Watts, T. W. K. Ng, J. Hua, S. Song, and P. H. R. Barrett, “Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men,” Diabetes, Obesity and Metabolism, vol. 8, no. 6, pp. 698–702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. E. L. Thomas, G. Hamilton, N. Patel et al., “Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study,” Gut, vol. 54, no. 1, pp. 122–127, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. D. van der Poorten, K.-L. Milner, J. Hui et al., “Visceral fat: a key mediator of steatohepatitis in metabolic liver disease,” Hepatology, vol. 48, no. 2, pp. 449–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. E. González-Reimers, A. Castellano-Higuera, R. Alemán-Valls et al., “Relation between body fat and liver fat accumulation and cytokine pattern in non-alcoholic patients with chronic HCV infection,” Annals of Nutrition and Metabolism, vol. 55, no. 4, pp. 351–357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. L. F. Hourigan, G. A. Macdonald, D. Purdie et al., “Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis,” Hepatology, vol. 29, no. 4, pp. 1215–1219, 1999. View at Scopus
  79. M. C. Amato, C. Giordano, M. Galia et al., “Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk,” Diabetes Care, vol. 33, no. 4, pp. 920–922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. J. R. Ticehurst, F. M. Hamzeh, and D. L. Thomas, “Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis,” Journal of Clinical Microbiology, vol. 45, no. 8, pp. 2426–2433, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Chen, T. Wong, G. Tomlinson, M. Krahn, and E. J. Heathcote, “Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic,” Journal of Hepatology, vol. 49, no. 5, pp. 711–717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. J. E. Everhart, A. S. Lok, H.-Y. Kim et al., “Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial,” Gastroenterology, vol. 137, no. 2, pp. 549–557, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Poordad, J. P. Bronowicki, S. C. Gordon, et al., “Factors that predict response of patients with hepatitis C virus infection to boceprevir,” Gastroenterology, vol. 143, pp. 608–618, 2012.
  84. H. Völzke, C. Schwahn, B. Wolff et al., “Hepatitis B and C virus infection and the risk of atherosclerosis in a general population,” Atherosclerosis, vol. 174, no. 1, pp. 99–103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. M. H. Lee, H. I. Yang, S. N. Lu, et al., “Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study,” Journal of Infectious Diseases, vol. 206, pp. 469–477, 2012.
  86. M. Boddi, R. Abbate, B. Chellini et al., “HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques,” Digestive and Liver Disease, vol. 39, no. 1, pp. S55–S60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Targher, L. Bertolini, R. Padovani, S. Rodella, G. Arcaro, and C. Day, “Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C,” Journal of Hepatology, vol. 46, no. 6, pp. 1126–1132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Ishizaka, N. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus core protein and carotid atherosclerosis,” Circulation Journal, vol. 67, no. 1, pp. 26–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Ishizaka, Y. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening,” The Lancet, vol. 359, no. 9301, pp. 133–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Marzouk, J. Sass, I. Bakr et al., “Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt,” Gut, vol. 56, no. 8, pp. 1105–1110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Petta, D. Torres, G. Fazio et al., “Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations,” Hepatology, vol. 55, no. 5, pp. 1317–1323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. M.-H. Lee, H.-I. Yang, C.-H. Wang et al., “Hepatitis C virus infection and increased risk of cerebrovascular disease,” Stroke, vol. 41, no. 12, pp. 2894–2900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Boddi, R. Abbate, B. Chellini et al., “Hepatitis C virus RNA localization in human carotid plaques,” Journal of Clinical Virology, vol. 47, no. 1, pp. 72–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. L. E. Adinolfi, L. Restivo, R. Zampino et al., “Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis,” Atherosclerosis, vol. 221, no. 2, pp. 496–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Mostafa, M. K. Mohamed, M. Saeed et al., “Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors,” Gut, vol. 59, no. 8, pp. 1135–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. I. Miyajima, T. Kawaguchi, A. Fukami, et al., “Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area,” Journal of Gastroenterology, vol. 48, pp. 93–100, 2013.
  97. Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, and E. Elsheikh, “Associations of chronic hepatitis C with metabolic and cardiac outcomes,” Alimentary Pharmacology & Therapeutics, vol. 37, pp. 647–652, 2013. View at Publisher · View at Google Scholar
  98. M. T. Kitson and S. K. Roberts, “D-Livering the message: the importance of vitamin D status in chronic liver disease,” Journal of Hepatology, vol. 57, pp. 897–909, 2012.
  99. S. Petta, C. Cammà, C. Scazzone et al., “Low vitamin d serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C,” Hepatology, vol. 51, no. 4, pp. 1158–1167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Bitetto, G. Fattovich, C. Fabris et al., “Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C,” Hepatology, vol. 53, no. 4, pp. 1118–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M. T. Kitson, G. J. Dore, J. George, et al., “Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection,” Journal of Hepatology, vol. 58, pp. 467–472, 2013.
  102. K. Baur, J. C. Mertens, J. Schmitt et al., “Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin D Receptor (NR 1I1) variants on fibrosis progression rate in HCV patients,” Liver International, vol. 32, no. 4, pp. 635–643, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. C. M. Lange, J. Bojunga, E. Ramos-Lopez et al., “Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy,” Journal of Hepatology, vol. 54, no. 5, pp. 887–893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Willheim, R. Thien, K. Schrattbauer et al., “Regulatory effects of 1α,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 10, pp. 3739–3744, 1999. View at Scopus
  105. P. M. Timms, N. Mannan, G. A. Hitman et al., “Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?” Quarterly Journal of Medicine, vol. 95, no. 12, pp. 787–796, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Cigolini, M. P. Iagulli, V. Miconi, M. Galiotto, S. Lombardi, and G. Targher, “Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients,” Diabetes Care, vol. 29, no. 3, pp. 722–724, 2006. View at Scopus
  107. M. T. Cantorna, Y. Zhu, M. Froicu, and A. Wittke, “Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system,” The American Journal of Clinical Nutrition, vol. 80, no. 6, pp. 1717–1720, 2004. View at Scopus
  108. S. Abu-Mouch, Z. Fireman, J. Jarchovsky, and N. Assy, “The beneficial effect of vitamin D combined eg interferon and ribavirin for chronic HCV infection,” Hepatology, vol. 50, p. LB20, 2009.
  109. T. J. Wang, F. Zhang, J. B. Richards, et al., “Common genetic determinants of vitamin D insufficiency: a genome-wide association study,” The Lancet, vol. 376, pp. 180–188, 2010.
  110. S. Petta, S. Grimaudo, V. Di Marco, et al., “Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients,” Journal of Viral Hepatitis, vol. 20, no. 7, pp. 486–493, 2013.
  111. S. Petta, D. Ferraro, C. Cammà, et al., “Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C,” Antiviral Therapy, vol. 17, pp. 823–831, 2012.
  112. S. Abu-Mouch, Z. Fireman, J. Jarchovsky, A.-R. Zeina, and N. Assy, “Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients,” World Journal of Gastroenterology, vol. 17, no. 47, pp. 5184–5190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Nimer and A. Mouch, “Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients,” World Journal of Gastroenterology, vol. 18, no. 8, pp. 800–805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. M. R. Von Essen, M. Kongsbak, P. Schjerling, K. Olgaard, N. Ødum, and C. Geisler, “Vitamin D controls T cell antigen receptor signaling and activation of human T cells,” Nature Immunology, vol. 11, no. 4, pp. 344–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. D. Conte, M. Fraquelli, D. Prati, A. Colucci, and E. Minola, “Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women,” Hepatology, vol. 31, no. 3, pp. 751–755, 2000. View at Scopus
  116. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Deuffic-Burban, T. Poynard, and A.-J. Valleron, “Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model,” Journal of Viral Hepatitis, vol. 9, no. 2, pp. 114–122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. V. Di Martino, P. Lebray, R. P. Myers et al., “Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure,” Hepatology, vol. 40, no. 6, pp. 1426–1433, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Villa, R. Vukotic, C. Cammà, et al., “Reproductive status is associated with the severity of fibrosis in women with hepatitis C,” PLoS ONE, vol. 7, Article ID e44624, 2012.
  120. J. G. McHutchison, E. J. Lawitz, M. L. Shiffman et al., “Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,” New England Journal of Medicine, vol. 361, no. 6, pp. 580–593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. H. S. Conjeevaram, M. W. Fried, L. J. Jeffers et al., “Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1,” Gastroenterology, vol. 131, no. 2, pp. 470–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Villa, A. Karampatou, C. Camm et al., “Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C,” Gastroenterology, vol. 140, no. 3, pp. 818–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. E. Villa, C. Cammà, A. Di Leo et al., “Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α2A plus ribavirin in menopausal women with chronic hepatitis C,” Journal of Viral Hepatitis, vol. 19, pp. 640–649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Cieloszyk, D. Hartel, G. Moskaleva, and E. E. Schoenbaum, “Effects of hepatitis C virus infection on menopause status and symptoms,” Menopause, vol. 16, no. 2, pp. 401–406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. G. A. Bray, S. J. Nielsen, and B. M. Popkin, “Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity,” American Journal of Clinical Nutrition, vol. 79, no. 4, pp. 537–543, 2004. View at Scopus
  126. L. H. Tetri, M. Basaranoglu, E. M. Brunt, L. M. Yerian, and B. A. Neuschwander-Tetri, “Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent,” American Journal of Physiology, vol. 295, no. 5, pp. G987–G995, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. X. Ouyang, P. Cirillo, Y. Sautin et al., “Fructose consumption as a risk factor for non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 48, no. 6, pp. 993–999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. I. Aeberli, M. Hochuli, P. A. Gerber, et al., “Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial,” Diabetes Care, vol. 36, pp. 150–156, 2013.
  129. W. T. Lin, H. L. Huang, M. C. Huang, et al., “Effects on uric acid, body mass index and blood pressure in adolescents of consuming beverages sweetened with high-fructose corn syrup,” International Journal of Obesity, vol. 37, pp. 532–539, 2012.
  130. A. O. Odegaard, A. C. Choh, S. A. Czerwinski, B. Towne, and E. W. Demerath, “Sugar-sweetened and diet beverages in relation to visceral adipose tissue,” Obesity, vol. 20, no. 3, pp. 689–691, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. M. F. Abdelmalek, A. Suzuki, C. Guy et al., “Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 6, pp. 1961–1971, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. G. L. Tyson, P. A. Richardson, D. L. White, et al., “Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients,” Journal of Clinical Gastroenterology, vol. 47, no. 6, pp. 545–552, 2013.
  133. E. Arnesen, N. E. Huseby, T. Brenn, and K. Try, “The Tromso heart study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 46, no. 1, pp. 63–70, 1986. View at Scopus
  134. E. Casiglia, P. Spolaore, G. Ginocchio, and G. B. Ambrosio, “Unexpected effects of coffee consumption on liver enzymes,” European Journal of Epidemiology, vol. 9, no. 3, pp. 293–297, 1993. View at Scopus
  135. S. Honjo, S. Kono, M. P. Coleman et al., “Coffee consumption and serum aminotransferases in middle-aged Japanese men,” Journal of Clinical Epidemiology, vol. 54, no. 8, pp. 823–829, 2001. View at Publisher · View at Google Scholar · View at Scopus
  136. A. L. Klatsky, C. Morton, N. Udaltsova, and G. D. Friedman, “Coffee, cirrhosis, and transaminase enzymes,” Archives of Internal Medicine, vol. 166, no. 11, pp. 1190–1195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. C. E. Ruhl and J. E. Everhart, “Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States,” Gastroenterology, vol. 128, no. 1, pp. 24–32, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. N. D. Freedman, J. E. Everhart, K. L. Lindsay et al., “Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C,” Hepatology, vol. 50, no. 5, pp. 1360–1369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. S. C. Larsson and A. Wolk, “Coffee consumption and risk of liver cancer: a meta-analysis,” Gastroenterology, vol. 132, no. 5, pp. 1740–1745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. N. D. Freedman, T. M. Curto, K. L. Lindsay, E. C. Wright, R. Sinha, and J. E. Everhart, “Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C,” Gastroenterology, vol. 140, no. 7, pp. 1961–1969, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. C. Mancone, C. Steindler, L. Santangelo et al., “Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins,” Gut, vol. 60, no. 3, pp. 378–386, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. K. E. Corey, E. Kane, C. Munroe, L. L. Barlow, H. Zheng, and R. T. Chung, “Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up,” Hepatology, vol. 50, no. 4, pp. 1030–1037, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. D. Ramcharran, A. S. Wahed, H. S. Conjeevaram et al., “Associations between serum lipids and hepatitis C antiviral treatment efficacy,” Hepatology, vol. 52, no. 3, pp. 854–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. S. A. Harrison, L. Rossaro, K.-Q. Hu et al., “Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy,” Hepatology, vol. 52, no. 3, pp. 864–874, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. F. Angelico, S. Francioso, M. Del Ben et al., “Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 5, pp. 444–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Petta, C. Camma, V. Di Marco et al., “Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection,” Antiviral Therapy, vol. 14, no. 5, pp. 631–639, 2009. View at Scopus
  147. J. H. Li, X. Q. Lao, H. L. Tillmann et al., “Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection,” Hepatology, vol. 51, no. 6, pp. 1904–1911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. L. E. Adinolfi, D. Ingrosso, G. Cesaro et al., “Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C,” Hepatology, vol. 41, no. 5, pp. 995–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. P. Toniutto, C. Fabris, E. Falleti et al., “Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C,” Liver International, vol. 28, no. 2, pp. 257–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  150. G. Borgia, I. Gentile, G. Fortunato et al., “Homocysteine levels and sustained virological response to pegylated-interferon α2b plus ribavirin therapy for chronic hepatitis C: a prospective study,” Liver International, vol. 29, no. 2, pp. 248–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Petta, C. Bellia, A. Mazzola et al., “Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C,” Journal of Viral Hepatitis, vol. 12, pp. 465–472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Lonardo, P. Loria, F. Leonardi et al., “Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study,” Digestive and Liver Disease, vol. 34, no. 3, pp. 204–211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. Y. Li, C. Xu, C. Yu, L. Xu, and M. Miao, “Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study,” Journal of Hepatology, vol. 50, no. 5, pp. 1029–1034, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. Y.-J. Lee, H.-R. Lee, J.-H. Lee, Y.-H. Shin, and J.-Y. Shim, “Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 2, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  155. T. Yamada, S. Suzuki, M. Fukatsu, T. Wada, T. Yoshida, and T. Joh, “Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup,” Acta Gastro-Enterologica Belgica, vol. 73, no. 1, pp. 12–17, 2010. View at Scopus
  156. C. Xu, C. Yu, L. Xu, M. Miao, and Y. Li, “High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study,” PLoS ONE, vol. 5, no. 7, Article ID e11578, 2010. View at Publisher · View at Google Scholar · View at Scopus
  157. S. Ryu, Y. Chang, S.-G. Kim, J. Cho, and E. Guallar, “Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men,” Metabolism, vol. 60, no. 6, pp. 860–866, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. J. W. Lee, Y. K. Cho, M. C. Ryan et al., “Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study,” Gut and Liver, vol. 4, no. 3, pp. 378–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. S. Petta, C. Cammà, D. Cabibi, V. Di Marco, and A. Craxì, “Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 7, pp. 757–766, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Afzali, N. S. Weiss, E. J. Boyko, and G. N. Ioannou, “Association between serum uric acid level and chronic liver disease in the United States,” Hepatology, vol. 52, no. 2, pp. 578–589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. R. Pellicano, G. Puglisi, A. Ciancio et al., “Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?” Journal of Medical Virology, vol. 80, no. 4, pp. 628–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. S. Petta, F. S. Macaluso, C. Cammà, V. Di Marco, D. Cabibi, and A. Craxì, “Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection,” Liver International, vol. 32, pp. 1443–1450, 2012. View at Publisher · View at Google Scholar
  163. D. I. Feig, D.-H. Kang, and R. J. Johnson, “Medical progress: uric acid and cardiovascular risk,” New England Journal of Medicine, vol. 359, no. 17, pp. 1811–1821, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. N. L. Edwards, “The role of hyperuricemia in vascular disorders,” Current Opinion in Rheumatology, vol. 21, pp. 132–137, 2009. View at Publisher · View at Google Scholar
  165. L. Prokunina-Olsson, B. Muchmore, W. Tang, et al., “A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus,” Nature Genetics, vol. 45, pp. 164–171, 2013.